A Phase 1 interventional study of AZD5462 film-coated tablet and [14C]AZD5462 Solution for Infusion in Heart Failure, sponsored by AstraZeneca. Completed at 1 site in United Kingdom. Open to male participants aged 30 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-04.
Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 64 studies in Heart Failure by AstraZeneca — 6 open to participants now, 8 under way, 3 of them phase 3. Heart Failure · AstraZeneca.
Among the 64 studies in Heart Failure by AstraZeneca, this one is the 37th largest by enrollment of the 39 interventional ones that give a count, is one of 3 that started in 2025, is one of 13 in phase 1, and was the 62nd registered.
6,334 studies on the registry are indexed under Heart Failure; 1,392 are open to participants now.
Browse Heart Failure studies →6 of the 64 studies in Heart Failure by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Argentina, Australia and 29 more countries
Ages 18+
AstraZeneca · Sites in United States, Germany, Portugal and 2 more countries
Ages 18+
AstraZeneca · Sites in United States, Denmark, France and 1 more country
Ages 12–130
AstraZeneca · Sites in United States, Argentina, Australia and 32 more countries
Ages 40+
AstraZeneca · Sites in United States, Argentina, Australia and 36 more countries
Ages 18–130
By country, each count listing its studies:
Of the 966 Heart Failure studies recruiting now, 689 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.
This study: 30 Years to 65 Years · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
64 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 9 · Phase 3 16 · Phase 4 2
First in 1999; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 8 is below the median of 76 across 4,049 interventional studies indexed under Heart Failure.
Median enrollment 160 across the 39 interventional studies, 621 across the 25 observational. Of the 54 that completed or were terminated, 14 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
4 of the studies in Heart Failure by AstraZeneca that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06307652Phase 3AstraZenecaStudy to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function | 2027-04-16 |
| NCT06336330AstraZenecaReal-world Study on Dapagliflozin Usage in Patients With Heart Failure (HF) in Germany | 2026-12-31 |
| NCT07690436AstraZenecaRetinal Fundus Imaging and OCT Imaging for Ocular Detection of ATTR-CM | 2027-06-18 |
| NCT06675552AstraZenecaNon-interventional Study on Guideline Directed Medical Therapy for Patients With Heart Failure (HF) in Germany | 2027-06-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 64 studies in Heart Failure by AstraZeneca, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A study to investigate how the body breaks down and gets rid of the test medicine, AZD5462.
To help investigate this, the test medicine is radiolabelled, which means that the test medicine has a radioactive component (carbon-14), which helps us to track where the test medicine is in the body. The safety and tolerability of the test medicine will also be studied.
This is an open-label, two-period study designed to assess the mass balance recovery, absorption, metabolism, excretion of [14C]AZD5462 and the absolute bioavailability of AZD5462 in healthy male participants.
The study will take place at 1 site in Nottingham, and enrol 8 healthy men aged 30-65 years. The study will include 2 Periods:
The participants will be resident in the clinical unit throughout both study periods for a total of 12 nights. The total study duration is approximately up to 6 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In Period 1, participants will receive one oral dose of \[14C\]AZD5462. In Period 2, participants will receive one oral dose of AZD5462 and one intravenous dose of \[14C\]AZD5462.
Drug: AZD5462 film-coated tablet · Drug: [14C]AZD5462 Solution for Infusion · Drug: [14C]AZD5462 Oral Solution
Oral, fasted
Also known as: AZD5462
Intravenous, fasted
Also known as: AZD5462
Oral, fasted
Also known as: AZD5462
Amount of AZD5462 excreted (Ae) - Period 1
Mass balance recovery of total radioactivity of \[14C\]AZD5462 in urine and faecal samples
Time frame: Urine and faecal samples collected from pre-dose until 168 hours post-dose
Amount of AZD5462 excreted expressed as a percentage of the dose administered (Fe) - Period 1
Mass balance recovery of total radioactivity of \[14C\]AZD5462 in urine and faecal samples
Time frame: Urine and faecal samples collected from pre-dose until 168 hours post-dose
Cumulative amount of AZD5462 excreted (CumAe) - Period 1
Mass balance recovery of total radioactivity of \[14C\]AZD5462 in urine and faecal samples
Time frame: Urine and faecal samples collected from pre-dose until 168 hours post-dose
Cumulative amount of AZD5462 excreted expressed as a percentage of the dose administered (CumFe) - Period 1
Mass balance recovery of total radioactivity of \[14C\]AZD5462 in urine and faecal samples
Time frame: Urine and faecal samples collected from pre-dose until 168 hours post-dose
Absolute bioavailability - Period 2
Absolute bioavailability (F) based on AUC0-inf of oral and IV administration, adjusted for dose
Time frame: Plasma sample collection from pre-dose to 72 hours post-dose
Time of maximum observed concentration (tmax) for AZD5462 and total radioactivity - Period 1
PK of AZD5462 and \[14C\]AZD5462 in plasma
Time frame: Plasma sample collection from pre-dose to 168 hours post-dose
Maximum observed concentration (Cmax) for AZD5462 and total radioactivity - Period 1
PK of AZD5462 and \[14C\]AZD5462 in plasma
Time frame: Plasma sample collection from pre-dose to 168 hours post-dose
Area under the curve from time 0 to the time of last measurable concentration (AUC0-t) for AZD5462 and total radioactivity - Period 1
PK of AZD5462 and \[14C\]AZD5462 in plasma
Time frame: Plasma sample collection from pre-dose to 168 hours post-dose
Area under the curve from time of the last measurable concentration to infinity as a percentage of the area under the curve extrapolated to infinity (AUC0-extrap) for AZD5462 and total radioactivity - Period 1
PK of AZD5462 and \[14C\]AZD5462 in plasma
Time frame: Plasma sample collection from pre-dose to 168 hours post-dose
Terminal elimination half-life (t1/2) for AZD5462 and total radioactivity - Period 1
PK of AZD5462 and \[14C\]AZD5462 in plasma
Time frame: Plasma sample collection from pre-dose to 168 hours post-dose
First order rate constant associated with the terminal (log-linear) portion of the curve (λz) for AZD5462 and total radioactivity - Period 1
PK of AZD5462 and \[14C\]AZD5462 in plasma
Time frame: Plasma sample collection from pre-dose to 168 hours post-dose
Total body clearance calculated after a single extravascular administration where F (fraction of dose bioavailable) is unknown (CL/F) for AZD5462 and total radioactivity - Period 1
PK of AZD5462 and \[14C\]AZD5462 in plasma
Time frame: Plasma sample collection from pre-dose to 168 hours post-dose
Renal clearance calculated using plasma AUC (CLR) for AZD5462 and total radioactivity - Period 1
PK of AZD5462 and \[14C\]AZD5462 in plasma and urine
Time frame: Plasma sample collection from pre-dose to 168 hours post-dose
Apparent volume of distribution based on the terminal phase calculated using AUC(0 inf) after a single extravascular administration where F (fraction of dose bioavailable) is unknown (Vz/F) for AZD5462 and total radioactivity - Period 1
PK of AZD5462 and \[14C\]AZD5462 in plasma and urine
Time frame: Plasma sample collection from pre-dose to 168 hours post-dose
Area under the curve (AUC) of circulating plasma total radioactivity (TR) or accounting for 10% or more of the dose in excreta - Period 1
Identification of the chemical structure of each metabolite accounting for more than 10% by AUC of circulating TR or accounting for 10% or more of the dose in urine and faeces
Time frame: Plasma, urine and faecal samples from pre-dose until 168 hours post-dose
Blood:plasma concentration ratios - Period 1
Blood:plasma concentration ratios of total radioactivity
Time frame: Whole blood samples and plasma samples collected from pre-dose until 168 hours post-dose
Amount of unchanged AZD5462 excreted in urine (Ae) - Period 2
Recovery of total radioactivity of \[14C\]AZD5462 in urine
Time frame: Urine sample collection from pre-dose to 72 hours post-dose
Amount of unchanged AZD5462 excreted in urine expressed as a percentage of the radioactive dose administered (Fe) - Period 2
Recovery of total radioactivity of \[14C\]AZD5462 in urine
Time frame: Urine sample collection from pre-dose to 72 hours post-dose
Cumulative amount of unchanged AZD5462 excreted in urine (CumAe) - Period 2
Recovery of total radioactivity of \[14C\]AZD5462 in urine
Time frame: Urine sample collection from pre-dose to 72 hours post-dose
Cumulative amount of unchanged AZD5462 excreted in urine expressed as a percentage of the radioactive dose administered (CumFe) - Period 2
Recovery of total radioactivity of \[14C\]AZD5462 in urine
Time frame: Urine sample collection from pre-dose to 72 hours post-dose
Area under the curve from time 0 extrapolated to infinity (AUC0-inf) for AZD5462 and total radioactivity - Period 1
PK of AZD5462 and \[14C\]AZD5462 in plasma
Time frame: Plasma sample collection from pre-dose to 168 hours post-dose
Time of maximum observed concentration (tmax) for AZD5462 and [14C]AZD5462 - Period 2
PK of AZD5462 and \[14C\]AZD5462 in plasma
Time frame: Plasma sample collection from pre-dose to 72 hours post-dose
Maximum observed concentration (Cmax) for AZD5462 and [14C]AZD5462 - Period 2
PK of AZD5462 and \[14C\]AZD5462 in plasma
Time frame: Plasma sample collection from pre-dose to 72 hours post-dose
Area under the curve from time 0 extrapolated to infinity (AUC0-inf) for AZD5462 and [14C]AZD5462 - Period 2
PK of AZD5462 and \[14C\]AZD5462 in plasma
Time frame: Plasma sample collection from pre-dose to 72 hours post-dose
Area under the curve from time 0 to the time of last measurable concentration (AUC0-t) for AZD5462 and [14C]AZD5462 - Period 2
PK of AZD5462 and \[14C\]AZD5462 in plasma
Time frame: Plasma sample collection from pre-dose to 72 hours post-dose
Area under the curve from time of the last measurable concentration to infinity as a percentage of the area under the curve extrapolated to infinity (AUC0-extrap) for AZD5462 and [14C]AZD5462- Period 2
PK of AZD5462 and \[14C\]AZD5462 in plasma
Time frame: Plasma sample collection from pre-dose to 72 hours post-dose
Terminal elimination half-life (t1/2) for AZD5462 and [14C]AZD5462 - Period 2
PK of AZD5462 and \[14C\]AZD5462 in plasma
Time frame: Plasma sample collection from pre-dose to 72 hours post-dose
First order rate constant associated with the terminal (log-linear) portion of the curve (λz) for AZD5462 and [14C]AZD5462 - Period 2
PK of AZD5462 and \[14C\]AZD5462 in plasma
Time frame: Plasma sample collection from pre-dose to 72 hours post-dose
Total body clearance calculated after a single IV administration (CL) for AZD5462 and [14C]AZD5462 - Period 2
PK of AZD5462 and \[14C\]AZD5462 in plasma
Time frame: Plasma sample collection from pre-dose to 72 hours post-dose
Total body clearance calculated after a single extravascular administration where F (fraction of dose bioavailable) is unknown (CL/F) for AZD5462 and [14C]AZD5462 - Period 2
PK of AZD5462 and \[14C\]AZD5462 in plasma
Time frame: Plasma sample collection from pre-dose to 72 hours post-dose
Volume of distribution based on the terminal phase calculated using AUC(0-inf) after a single IV administration (Vz) for AZD5462 and [14C]AZD5462 - Period 2
PK of AZD5462 and \[14C\]AZD5462 in plasma
Time frame: Plasma sample collection from pre-dose to 72 hours post-dose
Apparent volume of distribution at steady state after a single IV administration (Vss) for AZD5462 and [14C]AZD5462 - Period 2
PK of AZD5462 and \[14C\]AZD5462 in plasma
Time frame: Plasma sample collection from pre-dose to 72 hours post-dose
Apparent volume of distribution based on the terminal phase calculated using AUC(0 inf) after a single extravascular administration where F (fraction of dose bioavailable) is unknown (Vz/F) for AZD5462 and [14C]AZD5462 - Period 2
PK of AZD5462 and \[14C\]AZD5462 in plasma
Time frame: Plasma sample collection from pre-dose to 72 hours post-dose
Number of subjects with treatment-related adverse events - Periods 1 and 2
To provide additional safety and tolerability information for AZD5462
Time frame: Through study duration, an average of 7 weeks
Plan to share: Yes — Qualified researchers can request access to anonymized individual participant-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. "Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Ran from May 2025 to primary completion in Jun 2025, 1 month.
Of 77 industry-sponsored phase 1 interventional studies under Heart Failure, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 16. This study's 1 month is below that.
Counting every sponsor, half of 131 studies reached it within 14 months; a quarter within 4 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pexerelgon